Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...

U.S. stocks closed on a firm note on Wednesday as investors reacted positively to some upbeat earnings updates and corporate news, ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

The "Cellular Starting Materials Market by Product, by Grade, by End-User, and By Region" report has been added to ...

Merck is taking an exclusive commercial license to the drug – called pimicotinib (ABSK021) – in China, Hong Kong, Macau, and Taiwan, with an option on rights for the rest of the world.

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

BEIJING -- The China Manned Space Agency (CMSA) unveiled logos on Monday for three key missions in China's manned space program this year: the launches of the crewed spaceships Shenzhou XX and ...